Sybil L Crawford1, Carolyn J Crandall2, Carol A Derby3, Samar R El Khoudary4, L Elaine Waetjen5, Mary Fischer1, Hadine Joffe6,7. 1. University of Massachusetts Medical School, Graduate School of Nursing, Worcester, MA. 2. Department of Medicine, David Geffen School of Medicine at University of California, Los Angeles, CA. 3. Departments of Neurology and Epidemiology and Population Health, Albert Einstein College of Medicine, New York, NY. 4. University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA. 5. University of California Davis School of Medicine, Sacramento, CA. 6. Connors Center for Women's Health and Gender Biology, Boston, MA. 7. Department of Psychiatry, Brigham and Women's Hospital, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA.
Abstract
OBJECTIVE: To better understand how to educate patients and providers about study findings relevant to treatment guidelines, we assessed pre- versus post-Women's Health Initiative (WHI) differences in menopausal hormone therapy (MHT) initiation and continuation and their correlates, and in women's reasons for initiation and discontinuation. METHODS: We analyzed survey data from up to 14 approximately annual visits over 17 years (1996-2013) from 3,018 participants in the Study of Women's Health Across the Nation, a prospective cohort study. We used logistic regression to compare pre- versus post-WHI associations of covariates with MHT initiation and continuation, and to compare pre- versus post-WHI reasons for initiation and continuation. RESULTS: MHT initiation dropped from 8.6% pre-WHI to 2.8% post-WHI (P < 0.0001), and the corresponding decrease in MHT continuation was 84.0% to 62.0% (P < 0.0001). Decreases in MHT initiation and continuation occurred across a range of participant subgroups, consistent with wide dissemination of post-WHI recommendations. However, contrary to current guidelines, we found large declines in MHT use in subgroups for whom MHT is often recommended, that is, younger women and those with more vasomotor symptoms. Post-WHI, women's reasons for MHT initiation and discontinuation reflected concerns highlighted by WHI results. The largest declines in initiation reasons were for reducing risks of osteoporosis and heart disease, whereas the largest increases in discontinuation reasons were for media reports and provider advice. CONCLUSIONS: Immediate post-WHI recommendations for MHT use were widely adopted. MHT risks documented in older women, however, may have led younger symptomatic women to forgo MHT for symptom relief.
OBJECTIVE: To better understand how to educate patients and providers about study findings relevant to treatment guidelines, we assessed pre- versus post-Women's Health Initiative (WHI) differences in menopausal hormone therapy (MHT) initiation and continuation and their correlates, and in women's reasons for initiation and discontinuation. METHODS: We analyzed survey data from up to 14 approximately annual visits over 17 years (1996-2013) from 3,018 participants in the Study of Women's Health Across the Nation, a prospective cohort study. We used logistic regression to compare pre- versus post-WHI associations of covariates with MHT initiation and continuation, and to compare pre- versus post-WHI reasons for initiation and continuation. RESULTS:MHT initiation dropped from 8.6% pre-WHI to 2.8% post-WHI (P < 0.0001), and the corresponding decrease in MHT continuation was 84.0% to 62.0% (P < 0.0001). Decreases in MHT initiation and continuation occurred across a range of participant subgroups, consistent with wide dissemination of post-WHI recommendations. However, contrary to current guidelines, we found large declines in MHT use in subgroups for whom MHT is often recommended, that is, younger women and those with more vasomotor symptoms. Post-WHI, women's reasons for MHT initiation and discontinuation reflected concerns highlighted by WHI results. The largest declines in initiation reasons were for reducing risks of osteoporosis and heart disease, whereas the largest increases in discontinuation reasons were for media reports and provider advice. CONCLUSIONS: Immediate post-WHI recommendations for MHT use were widely adopted. MHT risks documented in older women, however, may have led younger symptomatic women to forgo MHT for symptom relief.
Authors: Ellen B Gold; Sybil L Crawford; Janie F Shelton; Ping G Tepper; Carolyn J Crandall; Gail A Greendale; Karen A Matthews; Rebecca C Thurston; Nancy E Avis Journal: Menopause Date: 2017-01 Impact factor: 2.953
Authors: Hayden B Bosworth; Lori A Bastian; Steven C Grambow; Colleen M McBride; Celette Sugg Skinner; Laura Fish; Barbara K Rimer; Ilene C Siegler Journal: J Behav Med Date: 2005-02
Authors: Erica S Breslau; William W Davis; Lynne Doner; Ellen J Eisner; Nina R Goodman; Helen I Meissner; Barbara K Rimer; Jacques E Rossouw Journal: J Am Med Womens Assoc (1972) Date: 2003
Authors: Jacques E Rossouw; Garnet L Anderson; Ross L Prentice; Andrea Z LaCroix; Charles Kooperberg; Marcia L Stefanick; Rebecca D Jackson; Shirley A A Beresford; Barbara V Howard; Karen C Johnson; Jane Morley Kotchen; Judith Ockene Journal: JAMA Date: 2002-07-17 Impact factor: 56.272
Authors: Jacob P Christ; Marlise N Gunning; Giulia Palla; Marinus J C Eijkemans; Cornelis B Lambalk; Joop S E Laven; Bart C J M Fauser Journal: Fertil Steril Date: 2018-03-28 Impact factor: 7.329
Authors: Cynthia A Stuenkel; Susan R Davis; Anne Gompel; Mary Ann Lumsden; M Hassan Murad; JoAnn V Pinkerton; Richard J Santen Journal: J Clin Endocrinol Metab Date: 2015-10-07 Impact factor: 5.958
Authors: Stephanie V Koebele; Sarah E Mennenga; Mallori L Poisson; Lauren T Hewitt; Shruti Patel; Loretta P Mayer; Cheryl A Dyer; Heather A Bimonte-Nelson Journal: Horm Behav Date: 2020-09-25 Impact factor: 3.587
Authors: Ross L Prentice; Aaron K Aragaki; Rowan T Chlebowski; Shanshan Zhao; Garnet L Anderson; Jacques E Rossouw; Robert Wallace; Hailey Banack; Aladdin H Shadyab; Lihong Qi; Beverly M Snively; Margery Gass; JoAnn E Manson Journal: Am J Epidemiol Date: 2020-09-01 Impact factor: 4.897
Authors: Rebecca B Lawn; Kristen M Nishimi; Yongjoo Kim; Sun Jae Jung; Andrea L Roberts; Jennifer A Sumner; Rebecca C Thurston; Lori B Chibnik; Eric B Rimm; Andrew D Ratanatharathorn; Shaili C Jha; Karestan C Koenen; Shelley S Tworoger; Laura D Kubzansky Journal: Cancer Epidemiol Biomarkers Prev Date: 2020-12-21 Impact factor: 4.254
Authors: Brooke W Bullington; Andrew Edmonds; Catalina Ramirez; Lisa Rahangdale; Genevieve Neal-Perry; Deborah Konkle-Parker; Deborah Jones Weiss; Caitlin Moran; Elizabeth Topper Golub; Helen Cejtin; Dominika Seidman; Seble Kassaye; Tracey E Wilson; Anjali Sharma; Adaora A Adimora; Andrea K Knittel Journal: Menopause Date: 2022-06-01 Impact factor: 3.310
Authors: Macarius M Donneyong; Teng-Jen Chang; Joshua A Roth; McKenna Guilds; Daniel Ankrah; Mehdi Najafzadeh; Wendy Y Xu; Rowan T Chlebowski; Karen Margolis; JoAnn E Manson Journal: Menopause Date: 2020-06 Impact factor: 3.310
Authors: Helena Harder; Rachel M L Starkings; Lesley J Fallowfield; Usha Menon; Ian J Jacobs; Valerie A Jenkins Journal: Menopause Date: 2019-10 Impact factor: 2.953
Authors: Marc Blondon; Andrew K Timmons; Aaron J Baraff; James S Floyd; Laura B Harrington; Anna M Korpak; Nicholas L Smith Journal: Menopause Date: 2021-07-26 Impact factor: 3.310
Authors: Graeme L Fraser; Samuel Lederman; Arthur Waldbaum; Robin Kroll; Nanette Santoro; Misun Lee; Laurence Skillern; Steven Ramael Journal: Menopause Date: 2020-04 Impact factor: 3.310